It would seem MSB is a massively under valued stock by the valuation arguments above. I've said before we are sat on a number of call options with MSB. I'd certainly say a $20-30 million market cap would not be eventually beyond reason if they got approved for C-19 ARDS, why I was still so heavily invested in MSB at $5 before the trial was mucked up by the NIH. Its so binary. If they get approved on one application the others offer huge potential revenue propsects and a $60 million mkt cap perhaps not so unimaginable as it sounds.
I am on a US stem-cell company that is only phase II in a J&J partnership and has a $7 billion USD mkt cap. Novartis paertnerhsip another call option....
- Forums
- ASX - By Stock
- MSB
- $90 a share on COVID ARDS Authorization ?
$90 a share on COVID ARDS Authorization ?, page-20
-
- There are more pages in this discussion • 241 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.39 |
Change
-0.065(4.47%) |
Mkt cap ! $1.598B |
Open | High | Low | Value | Volume |
$1.43 | $1.43 | $1.39 | $2.859M | 2.043M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
18 | 167412 | $1.39 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.40 | 14278 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
19 | 167413 | 1.390 |
18 | 120672 | 1.385 |
35 | 259889 | 1.380 |
11 | 26917 | 1.375 |
10 | 116439 | 1.370 |
Price($) | Vol. | No. |
---|---|---|
1.395 | 14278 | 10 |
1.400 | 35262 | 17 |
1.405 | 41561 | 9 |
1.410 | 84184 | 11 |
1.415 | 72446 | 6 |
Last trade - 13.39pm 16/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |